This was used in patients with mutations of CYP24A1 and SLC34A3 gene, leading to persistently raised 1,25-dihydroxyvitamin D, hypercalcemia, hypercalciuria, and nephrocalcinosis/nephrolithiasis (38, 39). Here, CYP24A1 is linked to nephrolithiasis.